Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506566 | 0.99 | RAB9A (0.60) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6131224 | 0.81 | NPC1 (0.65) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL31173710 | 0.81 | NPC1 (0.65) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| SCHEMBL741714 | 0.79 | NPC1 (0.62) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL16650533 | 0.79 | ATM (0.64) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10444520 | 0.78 | NPC1 (0.61) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| SCHEMBL23630256 | 0.77 | NPC1 (0.57) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL22345164 | 0.76 | RAB9A (1.00) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8068701 | 0.76 | NPC1 (0.67) | NPC1RAB9AATMALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL2463013 | 0.76 | ALDH1A1 (0.56) | NPC1RAB9AATMALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189881-B2 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-1213288-B1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1189881-B1 | PROPANOIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | NPC1 2760/4885RAB9A 3410/4885ATM 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.